101. Effect of Human Papillomavirus Vaccine to Interrupt Recurrence of Vulvar and Anal Neoplasia (VIVA): A Randomized, Placebo-Controlled Trial

BACKGROUND: Anal and vulvar high-grade intraepithelial lesions (HSIL) often recur after primary treatment, with 30%-50% recurrence in the 5-years following treatment. Treatment for recurrent lesions can be uncomfortable, debilitating, and costly. The VIVA trial evaluated the effects of the nonavalen...

Descripción completa

Detalles Bibliográficos
Autores principales: Stankiewicz Karita, Helen C, Magaret, Amalia, Schouten, Jeffrey, Mao, Constance, Huh, Warner, Grieco, Verena, Seymour, Matthew, Varon, Dana, Doody, David, Fu xi, Long, Galloway, Denise, Wald, Anna, Madeleine, Margaret
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752068/
http://dx.doi.org/10.1093/ofid/ofac492.179

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752068/
http://dx.doi.org/10.1093/ofid/ofac492.179

Ejemplares similares